Table 1 Clinical and biological characteristics of breast carcinoma according to pathological response and Neo-Bioscore
Characteristics | n | Pathological response | Neo-Bioscore | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
pCRa | non-pCR | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
310 (100%) | 43 (13.8%) | 267 (86.2%) | 1 (0.3%) | 18 (5.8%) | 47 (15.2%) | 84 (27.1%) | 83 (26.8%) | 49 (15.8%) | 23 (7.4%) | 5 (1.6%) | |
Menopausal status | |||||||||||
Premenopausal | 148 (48%) | 21 (48.8%) | 127 (47.6%) | 0 (0%) | 10 (55.6%) | 31 (66%) | 42 (50.0%) | 33 (39.8%) | 22 (44.9%) | 8 (34.8%) | 2 (40%) |
Postmenopausal | 162 (52%) | 22 (51.1%) | 140 (52.4%) | 1 (100%) | 8 (44.4%) | 16 (34%) | 42 (50.0%) | 50 (60.2%) | 27 (55.1%) | 15 (65.2%) | 3 (60%) |
Histological grade | |||||||||||
I/II | 160 (52%) | 16 (37.2%) | 144 (53.9%) | 1 (100%) | 17 (94.4%) | 36 (76.6%) | 61 (72.6%) | 34 (41.0%) | 11 (22.4%) | 0 (0%) | 0 (0%) |
III | 150 (48%) | 27 (62.8%) | 123 (46.1%) | 0 (0%) | 1 (5.6%) | 11 (23.4%) | 23 (27.4%) | 49 (59.0%) | 38 (77.6%) | 23 (100%) | 5 (100%) |
Estrogen receptor | |||||||||||
Negative | 131 (42%) | 32 (74.4%) | 99 (37.1%) | 0 (0%) | 2 (11.1%) | 10 (21.3%) | 31 (36.9%) | 43 (51.8%) | 24 (49%) | 16 (69.6%) | 5 (100%) |
Allred 2–6 (< 70%) | 40 (13%) | 4 (9.3%) | 36 (13.5%) | 1 (100%) | 4 (22.2%) | 7 (14.9%) | 11 (13.1%) | 8 (9.6%) | 8 (16.3%) | 1 (4.3%) | 0 (0%) |
Allred 7–8 (≥70%) | 139 (45%) | 7 (16.3%) | 132 (49.4%) | 0 (0%) | 12 (66.7%) | 30 (63.8%) | 42 (50.0%) | 32 (38.6%) | 17 (34.7%) | 6 (26.1%) | 0 (0%) |
Ki-67 | |||||||||||
< 20% | 80 (26%) | 5 (11.6%) | 75 (28.1%) | 0 (0%) | 6 (33.3%) | 13 (27.7%) | 27 (32.1%) | 20 (24.1%) | 12 (24.5%) | 2 (8.7%) | 0 (0%) |
20–50% | 134 (43%) | 18 (41.9%) | 116 (43.4%) | 0 (0%) | 8 (44.5%) | 22 (46.8%) | 38 (45.2%) | 35 (42.2%) | 17 (34.7%) | 12 (52.2%) | 2 (40%) |
≥ 50% | 96 (31%) | 20 (46.5%) | 76 (28.5%) | 1 (100%) | 4 (22.2%) | 12 (25.5%) | 19 (22.7%) | 28 (33.7%) | 20 (40.8%) | 9 (39.1%) | 3 (60%) |
HER2 | |||||||||||
Negative | 236 (76%) | 24 (55.8%) | 212 (79.4%) | 0 (0%) | 10 (55.6%) | 28 (59.6%) | 62 (73.8%) | 66 (79.5%) | 45 (91.8%) | 20 (87.0%) | 5 (100%) |
Positive | 74 (24%) | 19 (44.2%) | 55 (20.6%) | 1 (100%) | 8 (44.4%) | 19 (40.4%) | 22 (26.2%) | 17 (20.5%) | 4 (8.2%) | 3 (13.0%) | 0 (0%) |
Subtype | |||||||||||
A | 59 (19%) | 1 (2.3%) | 58 (21.7%) | 0 (0%) | 5 (27.8%) | 9 (19.1%) | 18 (21.4%) | 16 (19.3%) | 10 (20.4%) | 1 (4.3%) | 0 (0%) |
B | 83 (27%) | 2 (4.7%) | 81 (30.3%) | 0 (0%) | 5 (27.8%) | 14 (29.8%) | 20 (23.8%) | 20 (24.1%) | 16 (32.7%) | 8 (34.8%) | 0 (0%) |
HER2 | 74 (24%) | 19 (44.2%) | 55 (20.6%) | 1 (100%) | 8 (40.4%) | 19 (40.5%) | 22 (26.2%) | 17 (20.5%) | 4 (8.2%) | 3 (13%) | 0 (0%) |
TN | 94 (30%) | 21 (48.8%) | 73 (27.4%) | 0 (0%) | 0 (0%) | 5 (10.6%) | 24 (28.6%) | 30 (36.1%) | 19 (38.7%) | 11 (47.9%) | 5 (100%) |
Size | |||||||||||
T1/T2 | 111 (36%) | 13 (30.2%) | 98 (36.7%) | 1 (100%) | 17 (94.4%) | 28 (59.6%) | 42 (50.0%) | 21 (25.3%) | 2 (4.1%) | 0 (0%) | 0 (0%) |
T3/T4 | 199 (64%) | 30 (69.8%) | 169 (63.3%) | 0 (0%) | 1 (5.6%) | 19 (40.4%) | 42 (50.0%) | 62 (74.7%) | 47 (95.9%) | 23 (100%) | 5 (100%) |
Axilla | |||||||||||
Negative | 82 (26%) | 15 (34.9%) | 67 (25.1%) | 1 (100%) | 12 (66.7%) | 24 (51.1%) | 24 (28.6%) | 11 (13.3%) | 9 (18.4%) | 1 (4.3%) | 0 (0%) |
N1 | 138 (45%) | 21 (48.8%) | 117 (43.8%) | 0 (0%) | 5 (27.8%) | 19 (40.4%) | 37 (44.0%) | 45 (54.2%) | 22 (44.9%) | 8 (34.8%) | 2 (40%) |
N2/N3 | 90 (29%) | 7 (16.3%) | 83 (31.1%) | 0 (0%) | 1 (5.6%) | 4 (8.5%) | 23 (27.4%) | 27 (32.5%) | 18 (36.7%) | 14 (60.9%) | 3 (60%) |
Stage | |||||||||||
I/II | 117 (38%) | 18 (41.9%) | 99 (37.1%) | 1 (100%) | 16 (88.9%) | 32 (68.1%) | 42 (50.0%) | 21 (25.3%) | 5 (10.2%) | 0 (0%) | 0 (0%) |
III | 193 (62%) | 25 (58.1%) | 168 (62.9%) | 0 (0%) | 2 (11.1%) | 15 (31.9%) | 42 (50.0%) | 62 (74.7%) | 44 (89.8%) | 23 (100%) | 5 (100%) |